Tetraphase Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference

WATERTOWN, Mass., April 7, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14th at 8:40 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.

A live audio webcast of the presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 90 days.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections. Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic. Tetraphase is conducting a global Phase 3 clinical program for eravacycline called IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline). This program includes two Phase 3 clinical trials: IGNITE 1 for the indication of complicated intra-abdominal infections and IGNITE 2 for the indication of complicated urinary tract infections.

CONTACT: Investor Contacts:
         Tetraphase Pharmaceuticals
         Teri Dahlman
         617-600-7040
         [email protected]

         Argot Partners
         Susan Kim
         212-600-1902
         [email protected]

         Media Contact:
         Sam Brown Inc.
         Mike Beyer
         773-463-4211
         [email protected]

You May Also Be Interested In

• Needham Starts Wealthfront Corporation (WLTH) at Buy
• Dogecoin News Today: DOGE’s Recent Weekly Rally Meets Remittix’s Confirmed November Token Debut
• Cardano Price Prediction: ADA Builds a Recovery Case Near $0.26 as Remittix’s November 24 Countdown Begins